319 related articles for article (PubMed ID: 30062756)
21. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
[TBL] [Abstract][Full Text] [Related]
22. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G
Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
Omura Y; Toiyama Y; Okugawa Y; Yin C; Shigemori T; Kusunoki K; Kusunoki Y; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Ohi M; Kusunoki M
Cancer Immunol Immunother; 2020 Dec; 69(12):2533-2546. PubMed ID: 32577816
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival.
Koyama Y; Morikawa T; Miyama Y; Miyakawa J; Kawai T; Kume H; Sawabe M; Ushiku T
Pathol Res Pract; 2020 Dec; 216(12):153219. PubMed ID: 33049447
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
[No Abstract] [Full Text] [Related]
26. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
Hong AM; Ferguson P; Dodds T; Jones D; Li M; Yang J; Scolyer RA
Oral Oncol; 2019 May; 92():33-39. PubMed ID: 31010620
[TBL] [Abstract][Full Text] [Related]
27. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
[TBL] [Abstract][Full Text] [Related]
28. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
29. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
Front Immunol; 2021; 12():679090. PubMed ID: 34054869
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.
Iacovelli R; Ciccarese C; Brunelli M; Bogina G; Munari E; Bimbatti D; Mosillo C; Fantinel E; Bria E; Martignoni G; Tortora G
J Immunother; 2019 Sep; 42(7):269-273. PubMed ID: 31261165
[TBL] [Abstract][Full Text] [Related]
32. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
33. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E
Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462
[TBL] [Abstract][Full Text] [Related]
34. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Powles T; Walker J; Andrew Williams J; Bellmunt J
Cancer Treat Rev; 2020 Jan; 82():101925. PubMed ID: 31785413
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
36. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Bellmunt J; Mullane SA; Werner L; Fay AP; Callea M; Leow JJ; Taplin ME; Choueiri TK; Hodi FS; Freeman GJ; Signoretti S
Ann Oncol; 2015 Apr; 26(4):812-817. PubMed ID: 25600565
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
Zhang B; Yu W; Feng X; Zhao Z; Fan Y; Meng Y; Hu S; Cui Y; He Q; Zhang H; Li D; He Z; Zhou L; Jin J; Han W
Med Oncol; 2017 May; 34(5):94. PubMed ID: 28409437
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
40. Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
Guo L; Song P; Xue X; Guo C; Han L; Fang Q; Ying J; Gao S; Li W
J Immunother; 2019; 42(6):215-220. PubMed ID: 31145232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
